Clinical Research Directory

1. Inclusion Criteria: 1. As determined by the investigator, the subject is able to understand and comply with the protocol requirements; 2. Subject or subject's legal representative (if applicable) sign and date the written informed consent or any privacy authorization document required prior to the commencement of the study process; 3. Age 40-60; 4. Female patients; 5. The subject has received artificial tear sodium hyaluronate treatment with eye drops three times a day, but the treatment has no effect for two weeks, and the clinical examination results are consistent with: * OSDI score ≥13; * Schirmer test \< 10mm/5min; * Tear break-up time \< 10s; * Fluorescein sodium staining on the ocular surface was positive. 2. Exclusion Criteria: 1. Eye exclusion criteria: * Subjects with other eye diseases such as glaucoma, cataract, uveitis, optic neuritis, etc.； * The subjects had undergone eye surgery (e.g., cataract surgery) within the last three months; * Subjects who wear contact lenses for a long time and are unwilling to remove them in the study; * The subject has received eye drops in the past 24 hours that may affect the clinical study. 2. Exclusion criteria related to infectious diseases: * The subject has fungal, bacterial or viral keratitis or conjunctivitis with evidence of infection; * The subject has chronic hepatitis B virus (HBV) infection or chronic hepatitis C virus (HCV) infection; * The subject has any identified congenital or acquired immunodeficiency (e.g., common immunodeficiency, human immunodeficiency HIV infection, organ transplantation); * The subject has active tuberculosis (TB positive); * Subjects receive any live vaccine within 30 days prior to screening. 3. Exclusion criteria for general circumstances: * The subject is allergic to the stem cell eye drops; * The subject has any unstable or uncontrolled cardiovascular, pulmonary, liver, kidney, gastrointestinal, urogenital, hematological, clotting, immunological, endocrine/metabolic, or other medical condition that the investigator deems to interfere with the study or endanger the safety of the subject; * Subjects had had any surgery requiring general anesthesia within 30 days prior to enrollment, or planned to have a larger procedure during the study period surgery; * Subjects have a history of severe neurological diseases, including stroke, multiple sclerosis, brain tumors, or neurodegenerative diseases； * The subjects had active psychosis, which the researchers thought might interfere with their compliance with the study process; * Lactating female subjects, or female subjects with positive serum pregnancy test results during the screening period, or positive urine pregnancy test results prior to study drug administration.